Premium
Quantitative analysis of the secretome of TGF‐β signaling‐deficient mammary fibroblasts
Author(s) -
Xu Baogang J.,
Yan Wenwei,
Jovanovic Bojana,
An Angel Q.,
Cheng Nikki,
Aakre Mary E.,
Yi Yajun,
Eng Jimmy,
Link Andrew J.,
Moses Harold L.
Publication year - 2010
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200900701
Subject(s) - autocrine signalling , paracrine signalling , stable isotope labeling by amino acids in cell culture , biology , microbiology and biotechnology , signal transduction , transforming growth factor , stromal cell , lysyl oxidase , tumor microenvironment , extracellular matrix , cytokine , transforming growth factor beta , mammary tumor , extracellular , quantitative proteomics , cancer research , proteomics , receptor , immunology , cancer , breast cancer , biochemistry , genetics , tumor cells , gene
Transforming growth factor β (TGF‐β) is a master regulator of autocrine and paracrine signaling pathways between a tumor and its microenvironment. Decreased expression of TGF‐β type II receptor (TβRII) in stromal cells is associated with increased tumor metastasis and shorter patient survival. In this study, SILAC quantitative proteomics was used to identify differentially externalized proteins in the conditioned media from the mammary fibroblasts with or without intact TβRII. Over 1000 proteins were identified and their relative differential levels were quantified. Immunoassays were used to further validate identification and quantification of the proteomic results. Differential expression was detected for various extracellular proteins, including proteases and their inhibitors, growth factors, cytokines, and extracellular matrix proteins. CXCL10, a cytokine found to be up‐regulated in the TβRII knockout mammary fibroblasts, is shown to directly stimulate breast tumor cell proliferation and migration. Overall, this study revealed hundreds of specific extracellular protein changes modulated by deletion of TβRII in mammary fibroblasts, which may play important roles in the tumor microenvironment. These results warrant further investigation into the effects of inhibiting the TGF‐β signaling pathway in fibroblasts because systemic inhibition of TGF‐β signaling pathways is being considered as a potential cancer therapy.